je.st
news
Tag: merck
Merck Prices $8.0 Billion Debt Offering
2015-02-06 01:37:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. (the Company) (NYSE:MRK), known as MSD outside of the United States and Canada, priced today an $8.0 billion public offering of senior unsecured notes (collectively, the Notes). The Notes include: $300 million of floating rate notes due February 2017 $700 million of floating rate notes due February 2020 $1,250 million of 1.850% notes due February 2020 $1,250 million of 2.350% notes due February 2022 Language: English Contact: Media:Lainie Keller, (908) 236-5036orSteve Cragle, (908) 740-1801orInvestor:Joe Romanelli, (908) 740-1986orJustin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: prices
offering
debt
billion
Real time feeder cattle prices available online from Merck and DVAuction
2015-02-05 20:44:34| Beef
The feeder cattle market is the best it’s ever been. The feeder cattle market is the most volatile it’s ever been. Both are correct. And that’s why keeping up-to-date with the feeder cattle market has become job one for many cow-calf producers, stocker operators and cattle feeders. read more
Merck tops Street 4Q forecasts
2015-02-04 14:42:27| Biotech - Topix.net
The Kenilworth, New Jersey-based company said it had profit of $2.54 per share. Earnings, adjusted for one-time gains and costs, were 87 cents per share.
Tags: street
tops
forecasts
merck
Drugmaker Merck posts spike in 4Q profit, beats forecasts
2015-02-04 14:42:26| Biotech - Topix.net
Drugmaker Merck & Co.' s fourth-quarter profit skyrocketed to $7.32 billion, skewed by an $11.2 billion gain from selling its consumer care business to Germany's Bayer AG.
Tags: posts
profit
beats
forecasts
Merck Announces Fourth-Quarter and Full-Year 2014 Financial Results
2015-02-04 13:02:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. Fourth-Quarter 2014 Non-GAAP EPS of $0.87, Excluding Certain Items; GAAP EPS of $2.54; Full-Year 2014 Non-GAAP EPS of $3.49, Excluding Certain Items; GAAP EPS of $4.07 2015 Full-Year Non-GAAP EPS Target of $3.32 to $3.47, Including a $0.27 Negative Impact From Foreign Exchange and Excluding Certain Items; GAAP EPS Range of $1.62 to $1.91 Fourth-Quarter 2014 Worldwide Sales of $10.5 Billion, a Decrease of 7 Percent, Reflecting Unfavorable Impact of Patent Expiries and Divestitures and a 3 Percent Negative Impact From Foreign Exchange Full-Year 2014 Worldwide Sales of $42.2 Billion, a Decrease of 4 Percent, Reflecting Unfavorable Impact of Patent Expiries and Divestitures and a 1 Percent Negative Impact From Foreign Exchange Full-Year Results Reflect Sales Growth in Immunology, Diabetes, Hospital Acute Care, Vaccines and Animal Health and Sales Declines in Hepatitis C Six New Products Were Approved in the United States in 2014; Company Accelerated KEYTRUDA and Hepatitis C Clinical Development Programs KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2014. Language: English Contact: MerckMedia:Lainie Keller, 908-236-5036Steven Cragle, 908-740-1801orInvestors:Justin Holko, 908-740-1879Joe Romanelli, 908-740-1986 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
financial
announces
merck
Sites : [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] next »